Letter to the Editor: Looking Beyond the Numbers in NCCN Evidence Blocks
J Natl Compr Canc Netw. 2021 Mar 2;19(3):xlviia. doi: 10.6004/jnccn.2020.7676.NO ABSTRACTPMID:34521068 | DOI:10.6004/jnccn.2020.7676 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - September 14, 2021 Category: Cancer & Oncology Authors: Sang Kyu Cho Hankyung Jun Source Type: research

Authors' Reply To Letter to the Editor by Cho and Jun
J Natl Compr Canc Netw. 2021 Mar 2;19(3):xlviib-xlviiib. doi: 10.6004/jnccn.2020.7695.NO ABSTRACTPMID:34521069 | DOI:10.6004/jnccn.2020.7695 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - September 14, 2021 Category: Cancer & Oncology Authors: Aaron Mitchell Peter Bach Source Type: research

Letter to the Editor: Looking Beyond the Numbers in NCCN Evidence Blocks
J Natl Compr Canc Netw. 2021 Mar 2;19(3):xlviia. doi: 10.6004/jnccn.2020.7676.NO ABSTRACTPMID:34521068 | DOI:10.6004/jnccn.2020.7676 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - September 14, 2021 Category: Cancer & Oncology Authors: Sang Kyu Cho Hankyung Jun Source Type: research

Authors' Reply To Letter to the Editor by Cho and Jun
J Natl Compr Canc Netw. 2021 Mar 2;19(3):xlviib-xlviiib. doi: 10.6004/jnccn.2020.7695.NO ABSTRACTPMID:34521069 | DOI:10.6004/jnccn.2020.7695 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - September 14, 2021 Category: Cancer & Oncology Authors: Aaron Mitchell Peter Bach Source Type: research

Letter to the Editor: Looking Beyond the Numbers in NCCN Evidence Blocks
J Natl Compr Canc Netw. 2021 Mar 2;19(3):xlviia. doi: 10.6004/jnccn.2020.7676.NO ABSTRACTPMID:34521068 | DOI:10.6004/jnccn.2020.7676 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - September 14, 2021 Category: Cancer & Oncology Authors: Sang Kyu Cho Hankyung Jun Source Type: research

Authors' Reply To Letter to the Editor by Cho and Jun
J Natl Compr Canc Netw. 2021 Mar 2;19(3):xlviib-xlviiib. doi: 10.6004/jnccn.2020.7695.NO ABSTRACTPMID:34521069 | DOI:10.6004/jnccn.2020.7695 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - September 14, 2021 Category: Cancer & Oncology Authors: Aaron Mitchell Peter Bach Source Type: research

Importance of Family History of Colorectal Cancer In Situ Versus Invasive Colorectal Cancer: A Nationwide Cohort Study
CONCLUSIONS: Results of this study show that first-degree relatives and half-siblings of patients with CCIS have an increased risk of CRC, which is comparable in magnitude to the risk of those with a family history of invasive CRC. These findings extend available evidence on familial risk of CRC and may help to refine guidelines and recommendations for CRC screening.PMID:34517339 | DOI:10.6004/jnccn.2021.7004 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - September 13, 2021 Category: Cancer & Oncology Authors: Yu Tian Elham Kharazmi Hermann Brenner Xing Xu Kristina Sundquist Jan Sundquist Mahdi Fallah Source Type: research

Phase II Trial of Symptom Screening With Targeted Early Palliative Care for Patients With Advanced Cancer
J Natl Compr Canc Netw. 2021 Sep 7:1-10. doi: 10.6004/jnccn.2020.7803. Online ahead of print.ABSTRACTBACKGROUND: Routine early palliative care (EPC) improves quality of life (QoL) for patients with advanced cancer, but it may not be necessary for all patients. We assessed the feasibility of Symptom screening with Targeted Early Palliative care (STEP) in a phase II trial.METHODS: Patients with advanced cancer were recruited from medical oncology clinics. Symptoms were screened at each visit using the Edmonton Symptom Assessment System-revised (ESAS-r); moderate to severe scores (screen-positive) triggered an email to a pall...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - September 7, 2021 Category: Cancer & Oncology Authors: Camilla Zimmermann Ashley Pope Breffni Hannon Monika K Krzyzanowska Gary Rodin Madeline Li Doris Howell Jennifer J Knox Natasha B Leighl Srikala Sridhar Amit M Oza Rebecca Prince Stephanie Lheureux Aaron R Hansen Anne Rydall Brittany Chow Leonie Herx Chri Source Type: research

Trajectories of Suffering in the Last Year of Life Among Patients With a Solid Metastatic Cancer
CONCLUSIONS: The course of suffering during the last year of life among patients with cancer is variable and related to patients' hospitalizations. Understanding this variation can facilitate clinical decisions to minimize suffering and reduce healthcare costs at the end of life.PMID:34492633 | DOI:10.6004/jnccn.2021.7014 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - September 7, 2021 Category: Cancer & Oncology Authors: Chetna Malhotra Rahul Malhotra Filipinas Bundoc Irene Teo Semra Ozdemir Noreen Chan Eric Finkelstein Source Type: research

Phase II Trial of Symptom Screening With Targeted Early Palliative Care for Patients With Advanced Cancer
J Natl Compr Canc Netw. 2021 Sep 7:1-10. doi: 10.6004/jnccn.2020.7803. Online ahead of print.ABSTRACTBACKGROUND: Routine early palliative care (EPC) improves quality of life (QoL) for patients with advanced cancer, but it may not be necessary for all patients. We assessed the feasibility of Symptom screening with Targeted Early Palliative care (STEP) in a phase II trial.METHODS: Patients with advanced cancer were recruited from medical oncology clinics. Symptoms were screened at each visit using the Edmonton Symptom Assessment System-revised (ESAS-r); moderate to severe scores (screen-positive) triggered an email to a pall...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - September 7, 2021 Category: Cancer & Oncology Authors: Camilla Zimmermann Ashley Pope Breffni Hannon Monika K Krzyzanowska Gary Rodin Madeline Li Doris Howell Jennifer J Knox Natasha B Leighl Srikala Sridhar Amit M Oza Rebecca Prince Stephanie Lheureux Aaron R Hansen Anne Rydall Brittany Chow Leonie Herx Chri Source Type: research

Trajectories of Suffering in the Last Year of Life Among Patients With a Solid Metastatic Cancer
CONCLUSIONS: The course of suffering during the last year of life among patients with cancer is variable and related to patients' hospitalizations. Understanding this variation can facilitate clinical decisions to minimize suffering and reduce healthcare costs at the end of life.PMID:34492633 | DOI:10.6004/jnccn.2021.7014 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - September 7, 2021 Category: Cancer & Oncology Authors: Chetna Malhotra Rahul Malhotra Filipinas Bundoc Irene Teo Semra Ozdemir Noreen Chan Eric Finkelstein Source Type: research

Phase II Trial of Symptom Screening With Targeted Early Palliative Care for Patients With Advanced Cancer
J Natl Compr Canc Netw. 2021 Sep 7:1-10. doi: 10.6004/jnccn.2020.7803. Online ahead of print.ABSTRACTBACKGROUND: Routine early palliative care (EPC) improves quality of life (QoL) for patients with advanced cancer, but it may not be necessary for all patients. We assessed the feasibility of Symptom screening with Targeted Early Palliative care (STEP) in a phase II trial.METHODS: Patients with advanced cancer were recruited from medical oncology clinics. Symptoms were screened at each visit using the Edmonton Symptom Assessment System-revised (ESAS-r); moderate to severe scores (screen-positive) triggered an email to a pall...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - September 7, 2021 Category: Cancer & Oncology Authors: Camilla Zimmermann Ashley Pope Breffni Hannon Monika K Krzyzanowska Gary Rodin Madeline Li Doris Howell Jennifer J Knox Natasha B Leighl Srikala Sridhar Amit M Oza Rebecca Prince Stephanie Lheureux Aaron R Hansen Anne Rydall Brittany Chow Leonie Herx Chri Source Type: research

Trajectories of Suffering in the Last Year of Life Among Patients With a Solid Metastatic Cancer
CONCLUSIONS: The course of suffering during the last year of life among patients with cancer is variable and related to patients' hospitalizations. Understanding this variation can facilitate clinical decisions to minimize suffering and reduce healthcare costs at the end of life.PMID:34492633 | DOI:10.6004/jnccn.2021.7014 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - September 7, 2021 Category: Cancer & Oncology Authors: Chetna Malhotra Rahul Malhotra Filipinas Bundoc Irene Teo Semra Ozdemir Noreen Chan Eric Finkelstein Source Type: research

Phase II Trial of Symptom Screening With Targeted Early Palliative Care for Patients With Advanced Cancer
J Natl Compr Canc Netw. 2021 Sep 7:1-10. doi: 10.6004/jnccn.2020.7803. Online ahead of print.ABSTRACTBACKGROUND: Routine early palliative care (EPC) improves quality of life (QoL) for patients with advanced cancer, but it may not be necessary for all patients. We assessed the feasibility of Symptom screening with Targeted Early Palliative care (STEP) in a phase II trial.METHODS: Patients with advanced cancer were recruited from medical oncology clinics. Symptoms were screened at each visit using the Edmonton Symptom Assessment System-revised (ESAS-r); moderate to severe scores (screen-positive) triggered an email to a pall...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - September 7, 2021 Category: Cancer & Oncology Authors: Camilla Zimmermann Ashley Pope Breffni Hannon Monika K Krzyzanowska Gary Rodin Madeline Li Doris Howell Jennifer J Knox Natasha B Leighl Srikala Sridhar Amit M Oza Rebecca Prince Stephanie Lheureux Aaron R Hansen Anne Rydall Brittany Chow Leonie Herx Chri Source Type: research

Trajectories of Suffering in the Last Year of Life Among Patients With a Solid Metastatic Cancer
CONCLUSIONS: The course of suffering during the last year of life among patients with cancer is variable and related to patients' hospitalizations. Understanding this variation can facilitate clinical decisions to minimize suffering and reduce healthcare costs at the end of life.PMID:34492633 | DOI:10.6004/jnccn.2021.7014 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - September 7, 2021 Category: Cancer & Oncology Authors: Chetna Malhotra Rahul Malhotra Filipinas Bundoc Irene Teo Semra Ozdemir Noreen Chan Eric Finkelstein Source Type: research

Quantifying Withdrawal of Consent, Loss to Follow-Up, Early Drug Discontinuation, and Censoring in Oncology Trials
In this study, we sought to describe the planned handling and transparency of censoring data in oncology trials supporting FDA approval and to compare EDD and WCLFU in experimental and control arms.METHODS: We searched FDA archives to identify solid tumor drug approvals and their associated trials between 2015 and 2019, and extracted the planned handling and reporting of censored data. We compared the proportion of WCLFU and EDD between the experimental and control arms by using generalized estimating equations, and performed logistic regression to identify trial characteristics associated with WCLFU occurring more frequen...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - September 3, 2021 Category: Cancer & Oncology Authors: Brooke E Wilson Michelle B Nadler Alexandra Desnoyers Eitan Amir Source Type: research

First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort
CONCLUSIONS: Based on population-based data in patients with metastatic PDAC, treatment predominantly consists of FOLFIRINOX in the first line and gemcitabine with or without nab-paclitaxel in the second line. FOLFIRINOX in the first line shows superior OS compared with gemcitabine with or without nab-paclitaxel.PMID:34450595 | DOI:10.6004/jnccn.2021.7028 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 27, 2021 Category: Cancer & Oncology Authors: Esther N Pijnappel Willemieke P M Dijksterhuis Lydia G van der Geest Judith de Vos-Geelen Jan Willem B de Groot Marjolein Y V Homs Geert-Jan Creemers Nadia Haj Mohammad Marc G Besselink Hanneke W M van Laarhoven Johanna W Wilmink Dutch Pancreatic Cancer G Source Type: research

A Hospital-Wide Intervention to Improve Compliance With TNM Cancer Staging Documentation
J Natl Compr Canc Netw. 2021 Aug 27:1-10. doi: 10.6004/jnccn.2020.7799. Online ahead of print.ABSTRACTBACKGROUND: Accurate oncologic staging meeting clinical practice guidelines is essential for guideline adherence, quality assessment, and survival outcomes. However, timely and uniform documentation in the electronic health record (EHR) at the time of diagnosis is a challenge for providers. This quality improvement project aimed to increase provider compliance of timely clinical TNM (cTNM) or pathologic TNM (pTNM) staging for newly diagnosed oncologic patients.METHODS: Providers in the following site-specific oncologic tea...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 27, 2021 Category: Cancer & Oncology Authors: Jason H Lee Tariq Mohamed Celia Ramsey Jihoon Kim Shelly Kane Kathryn A Gold Farhoud Faraji Joseph A Califano Source Type: research

First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort
CONCLUSIONS: Based on population-based data in patients with metastatic PDAC, treatment predominantly consists of FOLFIRINOX in the first line and gemcitabine with or without nab-paclitaxel in the second line. FOLFIRINOX in the first line shows superior OS compared with gemcitabine with or without nab-paclitaxel.PMID:34450595 | DOI:10.6004/jnccn.2021.7028 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 27, 2021 Category: Cancer & Oncology Authors: Esther N Pijnappel Willemieke P M Dijksterhuis Lydia G van der Geest Judith de Vos-Geelen Jan Willem B de Groot Marjolein Y V Homs Geert-Jan Creemers Nadia Haj Mohammad Marc G Besselink Hanneke W M van Laarhoven Johanna W Wilmink Dutch Pancreatic Cancer G Source Type: research

A Hospital-Wide Intervention to Improve Compliance With TNM Cancer Staging Documentation
J Natl Compr Canc Netw. 2021 Aug 27:1-10. doi: 10.6004/jnccn.2020.7799. Online ahead of print.ABSTRACTBACKGROUND: Accurate oncologic staging meeting clinical practice guidelines is essential for guideline adherence, quality assessment, and survival outcomes. However, timely and uniform documentation in the electronic health record (EHR) at the time of diagnosis is a challenge for providers. This quality improvement project aimed to increase provider compliance of timely clinical TNM (cTNM) or pathologic TNM (pTNM) staging for newly diagnosed oncologic patients.METHODS: Providers in the following site-specific oncologic tea...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 27, 2021 Category: Cancer & Oncology Authors: Jason H Lee Tariq Mohamed Celia Ramsey Jihoon Kim Shelly Kane Kathryn A Gold Farhoud Faraji Joseph A Califano Source Type: research

First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort
CONCLUSIONS: Based on population-based data in patients with metastatic PDAC, treatment predominantly consists of FOLFIRINOX in the first line and gemcitabine with or without nab-paclitaxel in the second line. FOLFIRINOX in the first line shows superior OS compared with gemcitabine with or without nab-paclitaxel.PMID:34450595 | DOI:10.6004/jnccn.2021.7028 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 27, 2021 Category: Cancer & Oncology Authors: Esther N Pijnappel Willemieke P M Dijksterhuis Lydia G van der Geest Judith de Vos-Geelen Jan Willem B de Groot Marjolein Y V Homs Geert-Jan Creemers Nadia Haj Mohammad Marc G Besselink Hanneke W M van Laarhoven Johanna W Wilmink Dutch Pancreatic Cancer G Source Type: research

A Hospital-Wide Intervention to Improve Compliance With TNM Cancer Staging Documentation
J Natl Compr Canc Netw. 2021 Aug 27:1-10. doi: 10.6004/jnccn.2020.7799. Online ahead of print.ABSTRACTBACKGROUND: Accurate oncologic staging meeting clinical practice guidelines is essential for guideline adherence, quality assessment, and survival outcomes. However, timely and uniform documentation in the electronic health record (EHR) at the time of diagnosis is a challenge for providers. This quality improvement project aimed to increase provider compliance of timely clinical TNM (cTNM) or pathologic TNM (pTNM) staging for newly diagnosed oncologic patients.METHODS: Providers in the following site-specific oncologic tea...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 27, 2021 Category: Cancer & Oncology Authors: Jason H Lee Tariq Mohamed Celia Ramsey Jihoon Kim Shelly Kane Kathryn A Gold Farhoud Faraji Joseph A Califano Source Type: research

Efficacy and Toxicity Analysis of Capecitabine and Temozolomide in Neuroendocrine Neoplasms
The objective radiographic response rate was 46%, and the disease control rate was 81%. Median progression-free survival (PFS) was 18 months (95% CI, 14.0-21.9 months) and median overall survival was 51 months (95% CI, 42.8-59.2 months): 62 months in well-differentiated NETs versus 14 months in poorly differentiated neuroendocrine carcinomas (P
Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 25, 2021 Category: Cancer & Oncology Authors: Taymeyah Al-Toubah Eleonora Pelle Tiffany Valone Mintallah Haider Jonathan R Strosberg Source Type: research

The Microbiome Colorectal Cancer Puzzle: Initiator, Propagator, and Avenue for Treatment and Research
This article reviews the various mechanisms that bacteria in the gut use to induce and/or promote tumor formation, discusses the application of the microbiome in the prevention and therapy of CRC, and provides directions for future research endeavors aiming to develop a more complete understanding of this complex phenomenon.PMID:34416704 | DOI:10.6004/jnccn.2021.7062 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 20, 2021 Category: Cancer & Oncology Authors: Reece J Knippel Cynthia L Sears Source Type: research

Impact of the First Generation of Children's Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor
J Natl Compr Canc Netw. 2021 Aug 1;19(8):978-985. doi: 10.6004/jnccn.2021.7070.ABSTRACTRefinements in surgery, radiation therapy, and chemotherapy since the mid-20th century have resulted in a survival rate exceeding 90% for patients with Wilms tumor (WT). Although this figure is remarkable, a significant proportion of patients continue to have event-free survival (EFS) estimates of
Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 20, 2021 Category: Cancer & Oncology Authors: Jeffrey S Dome Elizabeth A Mullen David B Dix Eric J Gratias Peter F Ehrlich Najat C Daw James I Geller Murali Chintagumpala Geetika Khanna John A Kalapurakal Lindsay A Renfro Elizabeth J Perlman Paul E Grundy Conrad V Fernandez Source Type: research

NCCN Guidelines ® Insights: Uterine Neoplasms, Version 3.2021
J Natl Compr Canc Netw. 2021 Aug 1;19(8):888-895. doi: 10.6004/jnccn.2021.0038.ABSTRACTThe NCCN Guidelines for Uterine Neoplasms provide recommendations for diagnostic workup, clinical staging, and treatment options for patients with endometrial cancer or uterine sarcoma. These NCCN Guidelines Insights focus on the recent addition of molecular profiling information to aid in accurate diagnosis, classification, and treatment of uterine sarcomas.PMID:34416706 | DOI:10.6004/jnccn.2021.0038 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 20, 2021 Category: Cancer & Oncology Authors: Nadeem R Abu-Rustum Catheryn M Yashar Kristin Bradley Susana M Campos Junzo Chino Hye Sook Chon Christina Chu David Cohn Marta Ann Crispens Shari Damast Elisabeth Diver Christine M Fisher Peter Frederick David K Gaffney Suzanne George Robert Giuntoli Erne Source Type: research

Wilms Tumor (Nephroblastoma), Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
This article discusses the NCCN Guidelines recommendations for favorable histology WT.PMID:34416707 | DOI:10.6004/jnccn.2021.0037 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 20, 2021 Category: Cancer & Oncology Authors: Frank Balis Daniel M Green Clarke Anderson Shelly Cook Jasreman Dhillon Kenneth Gow Susan Hiniker Rama Jasty-Rao Chi Lin Harold Lovvorn Iain MacEwan Julian Martinez-Agosto Elizabeth Mullen Erin S Murphy Mark Ranalli Daniel Rhee Denise Rokitka Elisabeth Li Source Type: research

Pancreatic Cancer Progression in a Patient With Lynch Syndrome Receiving Immunotherapy: A Cautionary Tale
This report describes a patient with PDAC who experienced rapid disease progression suggestive of hyperprogressive disease. The case involved a 63-year-old man carrying a pathogenic germline PMS2 mutation who developed metastatic PDAC. His tumor showed isolated loss of PMS2 expression by immunohistochemistry (IHC). He was treated with pembrolizumab, but his disease rapidly progressed. Whole-genome and transcriptome sequencing of a liver metastasis biopsy, acquired at disease progression, showed a retained wild-type PMS2 allele and hallmarks of microsatellite stability, including low tumor mutational burden and low MSIsenso...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 20, 2021 Category: Cancer & Oncology Authors: Yifan Wang Adeline Cuggia Alain Pacis Jean-Christian Boileau Victoria A Marcus Zu-Hua Gao George Chong William D Foulkes George Zogopoulos Source Type: research

Diversity, Equity, and Representativeness: Coming to Terms With the Henrietta Lacks Act
J Natl Compr Canc Netw. 2021 Aug 1;19(8):993-996. doi: 10.6004/jnccn.2021.7071.NO ABSTRACTPMID:34416709 | DOI:10.6004/jnccn.2021.7071 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 20, 2021 Category: Cancer & Oncology Authors: Daniel J Boffa Keith B Churchwell Richard C Maduka Source Type: research

Authors' Reply: To the Letter to the Editor by Groheux et al
J Natl Compr Canc Netw. 2021 Aug 1;19(8):xxx-xxxii. doi: 10.6004/jnccn.2021.7080.NO ABSTRACTPMID:34416710 | DOI:10.6004/jnccn.2021.7080 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 20, 2021 Category: Cancer & Oncology Authors: Courtney Lawhn Heath Laura J Esserman Robert R Flavell Michelle E Melisko Source Type: research

Letter to the Editor: PET/CT in Locally Advanced Breast Cancer: Time for a Guideline Change?
J Natl Compr Canc Netw. 2021 Aug 1;19(8):xxx. doi: 10.6004/jnccn.2021.7050.NO ABSTRACTPMID:34416711 | DOI:10.6004/jnccn.2021.7050 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 20, 2021 Category: Cancer & Oncology Authors: David Groheux Elif Hindi é Marc Espi é Gary A Ulaner Source Type: research

Something to Crow About!
J Natl Compr Canc Netw. 2021 Aug 1;19(8):881-882. doi: 10.6004/jnccn.2021.0039.NO ABSTRACTPMID:34416712 | DOI:10.6004/jnccn.2021.0039 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 20, 2021 Category: Cancer & Oncology Authors: Margaret Tempero Source Type: research

The Microbiome Colorectal Cancer Puzzle: Initiator, Propagator, and Avenue for Treatment and Research
This article reviews the various mechanisms that bacteria in the gut use to induce and/or promote tumor formation, discusses the application of the microbiome in the prevention and therapy of CRC, and provides directions for future research endeavors aiming to develop a more complete understanding of this complex phenomenon.PMID:34416704 | DOI:10.6004/jnccn.2021.7062 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 20, 2021 Category: Cancer & Oncology Authors: Reece J Knippel Cynthia L Sears Source Type: research

Impact of the First Generation of Children's Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor
J Natl Compr Canc Netw. 2021 Aug 1;19(8):978-985. doi: 10.6004/jnccn.2021.7070.ABSTRACTRefinements in surgery, radiation therapy, and chemotherapy since the mid-20th century have resulted in a survival rate exceeding 90% for patients with Wilms tumor (WT). Although this figure is remarkable, a significant proportion of patients continue to have event-free survival (EFS) estimates of
Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 20, 2021 Category: Cancer & Oncology Authors: Jeffrey S Dome Elizabeth A Mullen David B Dix Eric J Gratias Peter F Ehrlich Najat C Daw James I Geller Murali Chintagumpala Geetika Khanna John A Kalapurakal Lindsay A Renfro Elizabeth J Perlman Paul E Grundy Conrad V Fernandez Source Type: research

NCCN Guidelines ® Insights: Uterine Neoplasms, Version 3.2021
J Natl Compr Canc Netw. 2021 Aug 1;19(8):888-895. doi: 10.6004/jnccn.2021.0038.ABSTRACTThe NCCN Guidelines for Uterine Neoplasms provide recommendations for diagnostic workup, clinical staging, and treatment options for patients with endometrial cancer or uterine sarcoma. These NCCN Guidelines Insights focus on the recent addition of molecular profiling information to aid in accurate diagnosis, classification, and treatment of uterine sarcomas.PMID:34416706 | DOI:10.6004/jnccn.2021.0038 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 20, 2021 Category: Cancer & Oncology Authors: Nadeem R Abu-Rustum Catheryn M Yashar Kristin Bradley Susana M Campos Junzo Chino Hye Sook Chon Christina Chu David Cohn Marta Ann Crispens Shari Damast Elisabeth Diver Christine M Fisher Peter Frederick David K Gaffney Suzanne George Robert Giuntoli Erne Source Type: research

Wilms Tumor (Nephroblastoma), Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
This article discusses the NCCN Guidelines recommendations for favorable histology WT.PMID:34416707 | DOI:10.6004/jnccn.2021.0037 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 20, 2021 Category: Cancer & Oncology Authors: Frank Balis Daniel M Green Clarke Anderson Shelly Cook Jasreman Dhillon Kenneth Gow Susan Hiniker Rama Jasty-Rao Chi Lin Harold Lovvorn Iain MacEwan Julian Martinez-Agosto Elizabeth Mullen Erin S Murphy Mark Ranalli Daniel Rhee Denise Rokitka Elisabeth Li Source Type: research

Pancreatic Cancer Progression in a Patient With Lynch Syndrome Receiving Immunotherapy: A Cautionary Tale
This report describes a patient with PDAC who experienced rapid disease progression suggestive of hyperprogressive disease. The case involved a 63-year-old man carrying a pathogenic germline PMS2 mutation who developed metastatic PDAC. His tumor showed isolated loss of PMS2 expression by immunohistochemistry (IHC). He was treated with pembrolizumab, but his disease rapidly progressed. Whole-genome and transcriptome sequencing of a liver metastasis biopsy, acquired at disease progression, showed a retained wild-type PMS2 allele and hallmarks of microsatellite stability, including low tumor mutational burden and low MSIsenso...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 20, 2021 Category: Cancer & Oncology Authors: Yifan Wang Adeline Cuggia Alain Pacis Jean-Christian Boileau Victoria A Marcus Zu-Hua Gao George Chong William D Foulkes George Zogopoulos Source Type: research

Diversity, Equity, and Representativeness: Coming to Terms With the Henrietta Lacks Act
J Natl Compr Canc Netw. 2021 Aug 1;19(8):993-996. doi: 10.6004/jnccn.2021.7071.NO ABSTRACTPMID:34416709 | DOI:10.6004/jnccn.2021.7071 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 20, 2021 Category: Cancer & Oncology Authors: Daniel J Boffa Keith B Churchwell Richard C Maduka Source Type: research

Authors' Reply: To the Letter to the Editor by Groheux et al
J Natl Compr Canc Netw. 2021 Aug 1;19(8):xxx-xxxii. doi: 10.6004/jnccn.2021.7080.NO ABSTRACTPMID:34416710 | DOI:10.6004/jnccn.2021.7080 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 20, 2021 Category: Cancer & Oncology Authors: Courtney Lawhn Heath Laura J Esserman Robert R Flavell Michelle E Melisko Source Type: research

Letter to the Editor: PET/CT in Locally Advanced Breast Cancer: Time for a Guideline Change?
J Natl Compr Canc Netw. 2021 Aug 1;19(8):xxx. doi: 10.6004/jnccn.2021.7050.NO ABSTRACTPMID:34416711 | DOI:10.6004/jnccn.2021.7050 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 20, 2021 Category: Cancer & Oncology Authors: David Groheux Elif Hindi é Marc Espi é Gary A Ulaner Source Type: research

Something to Crow About!
J Natl Compr Canc Netw. 2021 Aug 1;19(8):881-882. doi: 10.6004/jnccn.2021.0039.NO ABSTRACTPMID:34416712 | DOI:10.6004/jnccn.2021.0039 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 20, 2021 Category: Cancer & Oncology Authors: Margaret Tempero Source Type: research

The Microbiome Colorectal Cancer Puzzle: Initiator, Propagator, and Avenue for Treatment and Research
This article reviews the various mechanisms that bacteria in the gut use to induce and/or promote tumor formation, discusses the application of the microbiome in the prevention and therapy of CRC, and provides directions for future research endeavors aiming to develop a more complete understanding of this complex phenomenon.PMID:34416704 | DOI:10.6004/jnccn.2021.7062 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 20, 2021 Category: Cancer & Oncology Authors: Reece J Knippel Cynthia L Sears Source Type: research

Impact of the First Generation of Children's Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor
J Natl Compr Canc Netw. 2021 Aug 1;19(8):978-985. doi: 10.6004/jnccn.2021.7070.ABSTRACTRefinements in surgery, radiation therapy, and chemotherapy since the mid-20th century have resulted in a survival rate exceeding 90% for patients with Wilms tumor (WT). Although this figure is remarkable, a significant proportion of patients continue to have event-free survival (EFS) estimates of
Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 20, 2021 Category: Cancer & Oncology Authors: Jeffrey S Dome Elizabeth A Mullen David B Dix Eric J Gratias Peter F Ehrlich Najat C Daw James I Geller Murali Chintagumpala Geetika Khanna John A Kalapurakal Lindsay A Renfro Elizabeth J Perlman Paul E Grundy Conrad V Fernandez Source Type: research

NCCN Guidelines ® Insights: Uterine Neoplasms, Version 3.2021
J Natl Compr Canc Netw. 2021 Aug 1;19(8):888-895. doi: 10.6004/jnccn.2021.0038.ABSTRACTThe NCCN Guidelines for Uterine Neoplasms provide recommendations for diagnostic workup, clinical staging, and treatment options for patients with endometrial cancer or uterine sarcoma. These NCCN Guidelines Insights focus on the recent addition of molecular profiling information to aid in accurate diagnosis, classification, and treatment of uterine sarcomas.PMID:34416706 | DOI:10.6004/jnccn.2021.0038 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 20, 2021 Category: Cancer & Oncology Authors: Nadeem R Abu-Rustum Catheryn M Yashar Kristin Bradley Susana M Campos Junzo Chino Hye Sook Chon Christina Chu David Cohn Marta Ann Crispens Shari Damast Elisabeth Diver Christine M Fisher Peter Frederick David K Gaffney Suzanne George Robert Giuntoli Erne Source Type: research

Wilms Tumor (Nephroblastoma), Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
This article discusses the NCCN Guidelines recommendations for favorable histology WT.PMID:34416707 | DOI:10.6004/jnccn.2021.0037 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 20, 2021 Category: Cancer & Oncology Authors: Frank Balis Daniel M Green Clarke Anderson Shelly Cook Jasreman Dhillon Kenneth Gow Susan Hiniker Rama Jasty-Rao Chi Lin Harold Lovvorn Iain MacEwan Julian Martinez-Agosto Elizabeth Mullen Erin S Murphy Mark Ranalli Daniel Rhee Denise Rokitka Elisabeth Li Source Type: research

Pancreatic Cancer Progression in a Patient With Lynch Syndrome Receiving Immunotherapy: A Cautionary Tale
This report describes a patient with PDAC who experienced rapid disease progression suggestive of hyperprogressive disease. The case involved a 63-year-old man carrying a pathogenic germline PMS2 mutation who developed metastatic PDAC. His tumor showed isolated loss of PMS2 expression by immunohistochemistry (IHC). He was treated with pembrolizumab, but his disease rapidly progressed. Whole-genome and transcriptome sequencing of a liver metastasis biopsy, acquired at disease progression, showed a retained wild-type PMS2 allele and hallmarks of microsatellite stability, including low tumor mutational burden and low MSIsenso...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 20, 2021 Category: Cancer & Oncology Authors: Yifan Wang Adeline Cuggia Alain Pacis Jean-Christian Boileau Victoria A Marcus Zu-Hua Gao George Chong William D Foulkes George Zogopoulos Source Type: research

Diversity, Equity, and Representativeness: Coming to Terms With the Henrietta Lacks Act
J Natl Compr Canc Netw. 2021 Aug 1;19(8):993-996. doi: 10.6004/jnccn.2021.7071.NO ABSTRACTPMID:34416709 | DOI:10.6004/jnccn.2021.7071 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 20, 2021 Category: Cancer & Oncology Authors: Daniel J Boffa Keith B Churchwell Richard C Maduka Source Type: research